The new drug would allow patients to produce the needed clotting protein for an extended period, reducing the need for ...

The monoclonal antibody is the first non-factor, once-weekly treatment approved in the United States for hemophilia B.

Six months after scoring FDA approval for hemophilia B gene therapy Beqvez, Pf | For the second time in six months, the FDA ...

Patients suffering from hemophilia received a "meaningful" advancement on Friday when federal regulators approved the first ...

The U.S. Food and Drug Administration approved Pfizer's once-a-week injection for the two main types of a rare bleeding ...

The FDA will decide on new drugs for rosacea, AADC deficiency, breast cancer, transthyretin amyloid cardiomyopathy, and biliary tract cancer.

The FDA reported that the test accurately identified 99% of negative COVID-19 samples and 92% of positive samples. For the flu, the test showed 99.9% accuracy for negative samples and 92.5% and 90.5% ...

The U.S. Food and Drug Administration has approved Regeneron's Dupixent (dupilumab) as an add-on maintenance treatment for ...

A federal appeals court just handed the FDA the power to shut down some stem cell treatments. The ruling marks a major update ...

A new drug has been approved for the treatment of schizophrenia in adults. On Thursday, the U.S. Food and Drug Administration (FDA) approved COBENFY (xanomeline and trospium chloride), an oral ...

People with schizophrenia will have a new treatment option for the first time in more than three decades, after the Food and Drug Administration Thursday approved a new kind of drug. Studies ...

Today's approval provides a new option as people with schizophrenia move forward with proper support to rebuild their lives.” The FDA approval of COBENFY is supported by data from the EMERGENT ...